Home
overview

SMi’s 2nd Annual Conference
Ophthalmic Drugs
November 26th-27th, 2018 | London, United Kingdom
---------------------------------------------------------------------------
As the global population ages, the incidence of ophthalmic disorders continues to grow, and thus the interest of pharmaceutical and biotech companies is increasingly focused towards innovation of novel approaches for the development of ophthalmic drugs, driving the growth of this market. In fact, the global ophthalmic drug market is projected to reach £30 billion by 2023, growing at a CAGR of 5.3% from 2017 to 2023 (Via *Allied Market Research)

Join industry experts from Roche, Santen, Aerie Pharmaceuticals, MHRA, Nightstar Therapeutics and more to discuss and analyze the latest advancements and challenges within ophthalmic drug development. Network with industry professionals, explore novel approaches to treatment of ocular diseases, gain insight into ongoing clinical trials, discover how technology is revolutionising pharmaceutical R&D, and get invaluable advice on how to enhance development and overcome challenges within the industry.



 

Developing on last years success, this must-attend conference will bring together industry experts to discuss and analyse the latest advancements and challenges within ophthalmic drug development. Some notable areas of interest have been neuroprotection in ophthalmology, advancements in gene therapy, AMD clinical trial updates, and novel approaches for delivery of ocular drugs. Join us to network with ophthalmic experts from top pharmaceutical companies.

---------------------------------------------------------------
Exclusive Q&A sessions with speakers
on the latest developments within the Ophthalmic Drugs field
---------------------------------------------------------------

  • Philip Ashman - Alimera Sciences
  • David Silverman - Roche
  • Peter Morgan-Warren - MHRA
  • Mitchell de Long - Aerie Pharmaceuticals
  • Majid Anderesi - Roche
  • Caroline Barelle - Elasmogen
  • Naj Sharif - Santen

Interviews available on the Download Centre

Gain insight into...

  • The discovery of the first FDA-approved ROCK inhibitor for the treatment of glaucoma
  • Non-invasive drug delivery technology for anterior segment ocular disease
  • Novel treatments for Glaucoma / Retinoprotection
  • Advantages of site-specific biologics for ocular diseases
  • Current neuroprotective agents under investigation for the treatment of ocular disease
  • Exploring artificial intelligence in drug discovery
  • How to keep up with the ever changing regulatory environment, and to overcome challenges in regulation.
  • Gene delivery and gene editing in the retina

 

Key Job Titles:

Chief, Vice Presidents, Heads, Senior Directors, Directors, Principals, Principal Scientists, Team/ Project Leaders, Clinicians, Clinical Trial Managers, Medical Officers of:

  • Ophthalmology
  • Ophthalmic devices
  • Drug Delivery
  • Drug discovery
  • Research and development
  • Clinical development
  • Quality assurance
  • Immunology, Inflammation and Allergies
  • Market Access

Global Presence:

Attendees from all over the world attend our events, gain hands on insight from representatives from UK, Europe and USA.
 

Aerie Pharmaceuticals; Alimera Sciences; Altacor, Ltd; Annexin Pharmaceuticals AB; APTAR PHARMA; Bayer (Schweiz) AG; Biozep AS; Boehringer Ingelheim Pharma GmbH & Co. KG; Elasmogen Ltd; Envisia Therapeutics; Experimentica Ltd; Fresenius-Kabi; Leica Microsystems UK Ltd; MHRA; Midland Eye; Nanoptima Ltd; NEMERA; nicox; NightstarX; Novaliq GmbH; Ophthalmology Times Europe; Optos; Ora Inc; Oxford BioMedica; Partner Grup Pazarlama Iletisimi ve Tur Tic Ltd Sti; Pharmaleads; PharmaMedic Consultancy Ltd; Roche; Roche Diagnostics Ltd; Roche Products Ltd; Santen Incorporated; Shire; Similasan; UCL;

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Naj  Sharif

Naj Sharif, Executive Director in R&D, Head, Global Alliances & External Research, Santen Incorporated
View Bio

9:10 New strategies for treating retinal vascular diseases

Alan Stitt

Alan Stitt, Dean of Innovation and Impact, Queens University Belfast
View Bio

  • Overview for pathogenesis of ischaemic retinopathies
  • Cellular and molecular mechanisms of diseases
  • Targeting new pathways
  • Positioning preclinical evidence in the clinical setting to aid translation
  • Conclusions and future directions
  • 9:50 Gene delivery & gene editing in the retina

    Abraham  Scaria

    Abraham Scaria, Vice President Head of Ophthalmology, Casebia Therapeutics
    View Bio

  • Overview of methods for “in vivo” delivery to the retina
  • Gene delivery to different cell types in the retina
  • Crispr/Cas9 mediated gene editing in the retina

     

  • 10:30 Morning Coffee

    11:00 New horizon for treatment of inherited retinal distrophy

    Daniel  Chung

    Daniel Chung, Clinical Ophthalmic Lead, Spark Therapeutics
    View Bio

  • Voretigene: The first gene therapy approved in ophthalmology
  • Other up-coming gene therapy trials in the pipeline
  • Market access difficulties for gene therapy
  • 11:40 Current unmet needs for geographic atrophy- where are we now and where should we go?

    Victor Chong

    Victor Chong, Global Medical Head of Ophthalmology, Boehringer Ingelheim Pharma GmbH & Co. KG

  • Current unmet needs for Geographic Atrophy
  • Is Complement pathway the right place to go?
  • What about neuroprotection?
  • Is choroid more important than the RPE in GA?
  • 12:20 New ophthalmic drug delivery technologies

    Jens Peters

    Jens Peters, Reserach and Development, Aero Pump Gmbh
    View Bio

  • Preservative-free medications
  • Metered dose droppers
  • Fine mist spray technology for the opened eye
  • 13:00 Networking Lunch

    14:15 Genetically defined therapies in dry AMD

    Soraya Bekkali

    Soraya Bekkali, CEO, Gyroscope Therapeutics
    View Bio

  • Role of genetics in dry AMD
  • Gyroscopes approach to the treatment of dry AMD
  • Optimized drug delivery

     

  • 14:55 The future of ophthalmic delivery: preservative-free and connected devices

    Fanny Sellier

    Fanny Sellier, Global Category Manager, Ophthalmic Products, NEMERA
    View Bio

  • Understand the importance of patients’ adherence and the cause of the poor adherence today
  • Improve patients’ adherence by providing an easy to use, convenient and ergonomic system
  • Answer patients’ unmet needs by adding electronic guidance and connectivity
  • 15:35 Afternoon Tea

    16:05 Drug delivery strategies for retinal diseases

    Majid Anderesi

    Majid Anderesi, Associate Group Clinical Director Ophthalmology, Roche
    View Bio

  • Drug delivery to the posterior ocular segment: Challenges
  • Diseases affecting the posterior segment
  • Conventional versus novel routes for the drug delivery to the posterior segment
  • Conclusion
  • 16:45 soloMERs™ - site-specific biologics for ocular disease

    Caroline Barelle

    Caroline Barelle, CEO/CSO, Elasmogen Ltd
    View Bio

  • Advantages of soloMERs
  • Isolation and characterisation of target specific soloMERs
  • Efficacy in pre-clinical models of disease
  • Elasmogen’s ocular portfolio
  • 17:25 Chairman’s Closing Remarks and Close of Day One

    Naj  Sharif

    Naj Sharif, Executive Director in R&D, Head, Global Alliances & External Research, Santen Incorporated
    View Bio

    8:30 Registration & Coffee

    9:00 Chairman's Opening Remarks

    Mitchell de Long

    Mitchell de Long, Vice President, Chemistry, Aerie Pharmaceuticals
    View Bio

    9:10 Glaucoma / retinoprotection treatments

    Naj  Sharif

    Naj Sharif, Executive Director in R&D, Head, Global Alliances & External Research, Santen Incorporated
    View Bio

  • Recently approved & novel drugs in view
  • Novel devices to lower & control IOP
  • A case for & pathways to retinoprotection
  • 9:50 The discovery and SAR of Netarsudil, the first FDA-approved ROCK inhibitor for the treatment of glaucoma

    Mitchell de Long

    Mitchell de Long, Vice President, Chemistry, Aerie Pharmaceuticals
    View Bio

  • Need for new glaucoma medications after a period of focus on surgical treatment options
  • First FDA-approved ROCK inhibitor for the treatment of glaucoma
  • Future of the glaucoma landscape and back-of-the-eye disease
  • 10:30 Morning Coffee

    11:00 Standardization and validation of functional read-outs in preclinical ocular models

    Simon Kaja

    Simon Kaja, CSO, Experimentica Ltd
    View Bio

  • Requirement for validated reference compounds for in vivo studies
  • Utility of imaging and electrophysiology modalities in ocular models
  • Challenges associated with implementing in vivo functional readouts
     
  • 11:40 Application of artificial intelligence in drug discovery

    Andrew Radin

    Andrew Radin, Co-Founder and CEO, TwoXAR
    View Bio

  • Specific applications of predictive algorithms in drug research
  • How “predictions” translate into testable hypotheses and viable drug candidates
  • The future of artificial intelligence-driven drug discovery in ophthalmology
  • 12:20 Networking Lunch

    13:30 Regulatory considerations for clinical aspects of ocular drug development – established and surrogate end-points

    Peter Morgan Warren

    Peter Morgan Warren, Medical Assessor, MHRA
    View Bio

  • Overview of regulatory requirements for clinical approval of ophthalmic drugs
  • Trends in clinical trial efficacy end-points
  • Regulatory view on use of biomarkers and surrogate end-points in marketing authorisation submissions
  • Considerations for rare diseases – conditional marketing authorisations and exceptional circumstances
     
  • 14:10 Global reimbursement strategies in ophthalmic clinical development

    David  Silverman

    David Silverman, Senior Clinical Director, Ophthalmology, Roche
    View Bio

  • Introduction to global payer requirements
  • HTA Core Model
  • Use of patient reported outcomes in ophthalmic clinical trials
  • Structuring clinical development plans to meet payer requirements
  • 14:50 Afternoon Tea

    15:20 Challenges of delivering clinical trial results in the everyday clinic

    Philip Ashman

    Philip Ashman, Senior Vice President, Managing Director Europe, Alimera Sciences
    View Bio

  • Review the development of practice in treatment of diabetic macular oedema
  • The challenges accepting innovation into everyday practice
  • The emergence of "Real-World" data collection and lessons learned
  • A look into the future
  • 16:00 Natural history of disease studies in rare diseases

    Aniz Girach

    Aniz Girach, Chief Medical Officer, NightstarX
    View Bio

  • The value of running Natural History of Disease studies, especially in rare diseases
  • Why run Natural History of Disease studies?
  • Regulatory aspects of running Natural History of Disease studies
  • Natural History of Disease studies as part of running Innovative trial designs
  • 16:40 Chairman’s Closing Remarks and Close of Day Two

    Mitchell de Long

    Mitchell de Long, Vice President, Chemistry, Aerie Pharmaceuticals
    View Bio

    +

    FEATURED SPEAKERS

    Alan Stitt

    Alan Stitt

    Dean of Innovation and Impact, Queens University Belfast
    Daniel  Chung

    Daniel Chung

    Clinical Ophthalmic Lead, Spark Therapeutics
    David  Silverman

    David Silverman

    Senior Clinical Director, Ophthalmology, Roche
    Majid Anderesi

    Majid Anderesi

    Associate Group Clinical Director Ophthalmology, Roche
    Mitchell de Long

    Mitchell de Long

    Vice President, Chemistry, Aerie Pharmaceuticals
    Naj  Sharif

    Naj Sharif

    Executive Director in R&D, Head, Global Alliances & External Research, Santen Incorporated
    Peter Morgan Warren

    Peter Morgan Warren

    Medical Assessor, MHRA
    Victor Chong

    Victor Chong

    Global Medical Head of Ophthalmology, Boehringer Ingelheim Pharma GmbH & Co. KG

    Abraham Scaria

    Vice President Head of Ophthalmology, Casebia Therapeutics
    Abraham  Scaria

    Dr. Scaria obtained his Ph.D. in Molecular Biology from Indiana University School of Medicine in Indianapolis. He did postdoctoral training at St. Louis University School of Medicine working on RNA splicing mechanisms in adenoviruses and virus-host interactions. Dr. Scaria then worked as a Senior Fellow at University of Washington School of Medicine in Seattle before joining Genzyme Corporation to work on gene therapy for Cystic Fibrosis. At Genzyme and later at Sanofi-Genzyme, Dr. Scaria held various positions with increasing responsibilities for two decades finally heading up both the gene therapy research group and the ophthalmology research efforts. Currently, Dr. Scaria is the VP & Head of Ophthalmology at Casebia Therapeutics where he is developing gene-editing based therapies for ocular genetic diseases.

    Alan Stitt

    Dean of Innovation and Impact, Queens University Belfast
    Alan Stitt

    Prof Stitt is the McCauley Chair of Experimental Ophthalmology in Queen’s University Belfast. Prof Stitt’s research is in the inter-related areas of diabetic retinopathy, retinal angiogenesis and microvascular biology. His work has uncovered some key pathogenic pathways involved in neuroglial and microvascular dysfunction in the diabetic retina and this has led to the development and testing of several compounds that have progressed to clinical trials. He holds a Royal Society Wolfson Merit award and is the Editor of Current Eye Research, an Associate Editor for Diabetologia and currently sits on several other editorial board and panels.

    Andrew Radin

    Co-Founder and CEO, TwoXAR
    Andrew Radin

    Andrew A. Radin is Cofounder and Chief Executive Officer of twoXAR, a company dedicated to transforming how large biological datasets are harnessed to accelerate the identification and validation of new medicines. Andrew developed the company’s proprietary algorithm and leads product development. Prior to co-founding twoXAR, Andrew held Chief Technology Officer roles at several early stage companies where he managed teams as large as a hundred technologists distributed around the world. Andrew studied biomedical informatics in Stanford University’s SCPD graduate program and holds Master of Science and Bachelor of Science degrees in computer science from Rochester Institute of Technology.

    Aniz Girach

    Chief Medical Officer, NightstarX
    Aniz Girach

    Aniz Girach, qualified as an Ophthalmologist (specialty in Retina), and worked in Cambridge (UK). After having spent 11 years in the NHS, he joined the pharmaceutical industry with Eli Lilly, focusing on retinal diseases. He has in total 22 years industry experience in roles with Merck (as their Global Head of Ophthalmology) and Alcon, where he was Vice President of Clinical Development, and ThromboGenics, where he was the Global Head of Ophthalmology/Chief Medical Officer overseeing the development and approval of Ocriplasmin (Jetrea)—a first in class biologic therapy for retinal disease. In addition to an Honorary Professorship at Wills Eye Hospital, Philadelphia, USA, he is currently the Chief Medical Officer at Nightstar Therapeutics, overseeing the development of gene therapies for inherited retinal diseases. He is a member of 3 Scientific Advisory Boards for international ophthalmic organizations currently, and reviewer for 5 peer-reviewed journals, including Eye and IOVS. He has edited 4 books and published over 60 abstracts/manuscripts in peer-reviewed journals in Ophthalmology, with numerous invited lectures at national/international ophthalmology meetings. His special interests are Medical Retina, Vitreomacular Interface Abnormalities and Gene Therapy.

    Caroline Barelle

    CEO/CSO, Elasmogen Ltd
    Caroline Barelle

    Caroline is CEO and co-founder of Elasmogen, a company that discovers and develops soloMER biologics for site-specific treatment of inflammatory diseases and cancer. Before establishing Elasmogen, she successfully led teams at Wyeth and subsequently Pfizer in Global Bio-therapeutic Technologies progressing early platform technologies to late stage clinical development. Prior to this she was Alliance and Programs Manager at Haptogen Ltd and a key part of the acquisition team that successfully exited the business to Wyeth. She is a doctoral graduate from the University of Aberdeen in Biochemistry and a master graduate in business (MBA) from Robert Gordon’s University.

    Daniel Chung

    Clinical Ophthalmic Lead, Spark Therapeutics
    Daniel  Chung

    Dr. Chung is the Ophthalmology Lead for Clinical Development and Clinical R and D at Spark Therapeutics and the company’s inherited retinal disease resource. He also served as Spark’s Medical Affairs Ophthalmic Lead. In his current role, he works in the areas of clinical development and operations, marketing, commercial, patient advocacy, pre-clinical research and development and business development. Prior to joining Spark Therapeutics, he was a senior investigator/instructor at the FM Kirby Center for Molecular Ophthalmology at the Scheie Eye Institute at the Perelman School of Medicine of the University of Pennsylvania, working in retinal gene transfer and therapy. Concurrently, he served as the scientific advisor on the RPE65 gene therapy study team for phase 1 and 3 of the clinical trial at the Children’s Hospital of Philadelphia (CHOP). He was the lead designer of the Phase 3 MLMT novel endpoint, PI of the MLMT study, and PI of the RPE65 Natural History Study. He completed his ophthalmology residency in Akron, Ohio. He then completed fellowships in pediatric ophthalmology and ocular genetics research at the Cole Eye Institute at the Cleveland Clinic, and was a retinal gene therapy fellow at the National Eye Institute/NIH in Bethesda, MD
     

    David Silverman

    Senior Clinical Director, Ophthalmology, Roche
    David  Silverman

    David Silverman worked as an ophthalmologist in the UK before joining Quintiles to work in Phase 1 clinical trials. He subsequently spent nearly 6 years at the MHRA as a clinical assessor, reviewing applications and providing scientific advice for ophthalmic medicines for the UK and the EMA; he also served as a UK delegate on the CHMP’s Scientific Advice Working Party. David joined Roche in 2015, to work on ophthalmic global clinical development programs. He is a Fellow of the Faculty of Pharmaceutical Medicine, and has an MSc in Economic Evaluation for Health Technology Assessment from the University of York.

    Fanny Sellier

    Global Category Manager, Ophthalmic Products, NEMERA
    Fanny Sellier

    Fanny Sellier is responsible for developing the ophthalmic products at Nemera, including the new innovative preservative-free technology Novelia®. Fanny joined the company in 2011. A graduate from the ISEG business school in Strasbourg and the IUT de Chimie (chemical sciences) in Besancon. Fanny has worked seven years for Rhodia (now Solvay) in the U.S. in marketing, Lean enterprise and business development. She was then with BASF for a year in a marketing position managing products for the Home Care industry.
     

    Jens Peters

    Reserach and Development, Aero Pump Gmbh
    Jens Peters

    Jens Peters is responsible for the development of drug delivery devices at Aero Pump GmbH, such as the preservative-free Ophthalmic Multidose System. He was educated and trained at Christian-Albrechts-University in Kiel (Germany) where he completed his degree in physics.
    Jens started his professional career at Ursatec Verpackung GmbH, an innovative company in the field of preservative-free pump systems for medicinal applications. In 1999 he moved to Ursatec’s holding company Aero Pump where he took over the responsibility as R&D director.
     

    Majid Anderesi

    Associate Group Clinical Director Ophthalmology, Roche
    Majid Anderesi

    Majid Anderesi is an ophthalmologist by training. Prior to joining Roche, he held international positions with Pfizer, Novartis, Bayer, and Allergan. Majid currently works at Roche as Associate Group Clinical Director in Ophthalmology and as a member of Global Science Team.
     

    Mitchell de Long

    Vice President, Chemistry, Aerie Pharmaceuticals
    Mitchell de Long

    Mitchell A. (Mitch) deLong holds the position of vice president, Chemistry at Aerie Pharmaceuticals as well as Adjunct Professor of Chemistry at Duke University. Since Mitch helped to found Aerie as a Duke University spinout in 2005, Aerie has filed 5 INDs and 2 NDAs, with its first FDA approval coming in 2017. Aerie has grown from the initial 3-person team to over 300 employees, and went public on NASDAQ in 2013, where its current valuation is over $2 billion (US). Mitch is lead inventor on over 50 issued US patents, about half of those at Aerie, and has over 100 publications, posters and presentations. Mitch earned his PhD in Synthetic Organic and Medicinal Chemistry at Stanford University, and has two other marketed drugs to his credit.

    Naj Sharif

    Executive Director in R&D, Head, Global Alliances & External Research, Santen Incorporated
    Naj  Sharif

    Naj Sharif, PhD, FARVO, FBPhS was educated and trained in England at Southampton University (BSc (Joint Honors: Biochemistry and Physiology); PhD (Neuroscience)). His pharmaceutical industry experience (>32 years) includes holding leadership positions in discovery research, drug development and regulatory affairs at Pfizer, Syntex (Roche), Alcon-Novartis and Santen. His 22-tenure at Alcon resulted in his contributions to the discovery/development and US FDA approvals of Travatan®, Patanol®, Simbrinza®, and Pazeo® to treat glaucoma/ocular hypertension and ocular allergies. At Santen he has contributed towards the in-licensing and acquisition of InnFocus Microshunt, and to various drug candidates. He is a Fellow of ARVO (FARVO), and of British Pharmacological Society (FBPhS). Dr. Sharif received the inaugural Dr. Roger Vogel Award for ocular pharmaceutical research, and the “Sir James Black Award” for contributions to drug discovery. He serves on the editorial boards of numerous journals, and is an Adjunct Professor at several Universities. He has published >210 papers, edited 2 books, and is the holder of 23 issued patents.

    Peter Morgan Warren

    Medical Assessor, MHRA
    Peter Morgan Warren

    Dr Peter Morgan-Warren is a Medical Assessor at the Medicines & Healthcare products Regulatory Agency. After graduating in medicine from University of Oxford, Peter worked as a Medical Officer for the Royal Air Force, with clinical practice in both primary and secondary care and additional aviation medicine/administrative roles. He then went on to undertake specialist clinical training in ophthalmology in the West Midlands, and was appointed as the inaugural Medical Research Council/Royal College of Ophthalmologists John Lee Fellow in 2012 for his doctoral research programme into the development of novel biotherapeutics for neuroprotection and regeneration for optic neuropathy. He was awarded his PhD from University of Birmingham in 2016. Peter is now a Medical Assessor at the MHRA, involved in the review and assessment of regulatory submission for national and European medicinal products, and contribution to scientific advice provision for clinical development programmes.
     

    Philip Ashman

    Senior Vice President, Managing Director Europe, Alimera Sciences
    Philip Ashman

    Philip Ashman has worked in the pharmaceutical industry since completing his PhD. During this time, he has worked in numerous therapeutic areas, gaining experience in small and large pharmaceutical companies working a range of functions including clinical development, market access, sales and marketing. He joined Alimera Sciences in 2013 to lead the start-up of the organisation initially in Europe and more recently into the Middle East.

    Simon Chandler

    Senior Director , Ora Europe Ltd
    Simon Chandler

    Dr. Simon Chandler heads European BD for Ora, Europe and is Head of Gene and Cell based therapies for Ora Inc. He is based in the UK and holds a Ph.D. in epigenetics and molecular biology and from the University of Southampton. Ora is the world’s leading partner for ophthalmic pharmaceutical and device development, with expertise in a broad range of ophthalmic indications and offices in the United States, the United Kingdom, Australia and Japan

    Simon Kaja

    CSO, Experimentica Ltd
    Simon Kaja

    <p>Dr. Kaja joined Experimentica Ltd. as Chief Scientific Officer and Director North American Operations in August 2014. Dr. Kaja holds an academic appointment as Endowed Professor of Ophthalmology at Loyola University Chicago. He has previously held numerous positions in academia, biotech companies and the pharmaceutical industry and is a frequent consultant on drug discovery for ophthalmic disorders. In addition to his internationally recognized work on neurodegeneration and glaucoma, Dr. Kaja has significantly contributed to drug development for dry-eye disease and our understanding of the pathophysiology of migraine. Dr. Kaja earned his B.Sc. in molecular biology and biochemistry from Durham University (United Kingdom) and his Ph.D. in neuroscience from Leiden University (The Netherlands). <br /> &nbsp;</p>

    Soraya Bekkali

    CEO, Gyroscope Therapeutics
    Soraya Bekkali

    Soraya Bekkali is a board-certified MD graduated from Paris University specialized in Clinical Pharmacology and Biostatistics with 20 years of experience in Drug Development.
    She started her career in the academia before joining the industry with Orphan Europe, in the rare disease space. She then joined Sanofi for 9 years where she held increasing leadership positions within global R&D, leading gene therapy programs in cardiovascular and Ophthalmology. She took over the leadership of the Ophthalmology Division in 2012 and in this capacity, drove Sanofi strategy towards ocular gene therapy efforts while setting up a multidisciplinary R&D and business organization. In 2015, Soraya served as SVP CMO at Lysogene, a biotech developing gene therapy treatment for rare CNS disorders. As a member of the executive team, she contributed to the successful listing of Lysogene on the European Stock Exchange Euronext. Mid 2017, Soraya Bekkali was appointed at CEO and Director of the board of Gyroscope Therapeutics Ltd, a private company founded by Syncona and Cambridge Enterprise and supported by its scientific founders with expertise in ophthalmology, immunology and gene therapy.
    The company is headquartered the UK. Its mission is to develop genetically-defined therapies for the treatment of eye diseases linked to an unbalanced complement system, such as dry age related macular degeneration using gene therapy as a mode of treatment delivery.
     

    Victor Chong

    Global Medical Head of Ophthalmology, Boehringer Ingelheim Pharma GmbH & Co. KG
    Victor Chong

    Sponsors and Exhibitors

    Official Online Media Partners

    Supporting Media Partners

    Supporters

    Workshops

    Are Eye Drops the Best Route for Ophthalmic Therapy?
    Workshop

    Are Eye Drops the Best Route for Ophthalmic Therapy?

    Copthorne Tara Hotel
    28th November 2018
    London, United Kingdom

    VENUE

    Copthorne Tara Hotel

    Scarsdale Place, Kensington, London, United Kingdom

    The Copthorne Tara Hotel London Kensington is an elegant contemporary four-star hotel in prestigious Kensington, located just a two minutes walk from High Street Kensington underground station, making exploring easy. The hotel offers well-appointed and comfortable guest rooms combining Standard, Superior and Club accommodation. Club rooms offer iconic views over the city and include Club Lounge access for complimentary breakfast and refreshments. Guests can sample the authentic Singaporean, Malaysian and Chinese cuisine at Bugis Street, traditional pub fare at the Brasserie Restaurant & Bar or relax with a delicious drink at West8 Cocktail Lounge & Bar.

    The Copthorne Tara Hotel boasts 745 square meters of flexible meeting space, consisting of the Shannon Suite and the Liffey Suite, ideal for hosting conferences, weddings and social events. Facilities include access to the business centre 24 hours a day, fully equipped fitness room, gift shop, theatre desk and Bureau de Change. With ample onsite parking outside the London congestion charge zone and excellent transport links via Heathrow Airport, the hotel is the perfect location for business or leisure stays. The hotel is within close proximity to the shops of High Street Kensington, Knightsbridge and Westfield London, Olympia Conference Centre, Royal Albert Hall, Kensington Palace and Hyde Park.

     

    HOTEL BOOKING FORM

    Accelerating Ophthalmic Drug Discovery White Paper

    Download

    Trends in Antiglaucoma Topical Treatments (White Paper)

    Download

    Letter from the Chair

    Download

    2018 Attendee List

    Download

    [SPONSORSHIP MANUAL] - BECOME A 2019 SPONSOR

    Download

    [SPEAKER INTERVIEW] - PHILIP ASHMAN, ALIMERA SCIENCES

    Download

    [SPEAKER INTERVIEW] - DAVID SILVERMAN, ROCHE

    Download

    [SPEAKER INTERVIEW] - Peter Morgan-Warren, MHRA

    Download

    [ATTENDEE BREAKDOWN] - INFOGRAPHIC

    Download

    [SPEAKER INTERVIEW] - MITCHELL DE LONG, AERIE PHARMACEUTICALS

    Download

    [SPEAKER INTERVIEW] - Majid Anderesi, Roche

    Download

    [SPEAKERS 2018] - FULL LIST OF SPEAKERS

    Download

    [WORKSHOP A] - FULL DETAILS

    Download

    [WORKSHOP B] - FULL DETAILS

    Download

    [DAY 1] - FULL PROGRAMME

    Download

    [DAY 2] - FULL PROGRAMME

    Download

    [SPEAKER INTERVIEW] - CAROLINE BARELLE, ELASMOGEN

    Download

    [SPEAKER INTERVIEW] - NAJ SHARIF, SANTEN

    Download

    [2017 PRESENTATION] - Boehringer Ingelheim

    Download

    [2017 PRESENTATION] - AERIE PHARMACEUTICALS

    Download

    [2017 PRESENTATION] - NOVALIQ

    Download

    [FULL BROCHURE] - 2018

    Download

    [SPEAKER INTERVIEW] - Bernhard Guenther, Co-Founder, Chief Innovation Officer, Novaliq GmbH

    Download

    [2017 ATTENDEE LIST] - OPHTHALMIC DRUGS

    Download

    Sponsors and Exhibitors


    AERO PUMP

    Sponsors and Exhibitors
    http://www.aeropump.de

    AERO PUMP is a leading manufacturer of preservative-free eye dropper devices. Our Ophthalmic Multidose System is widely established in the OTC and Rx market. The 3K-technology avoids microbiological contamination inside the container without the need of preservatives in the formulation. Its exact metered dosing pump delivers an accurate drop size.


    Experimentica Ltd.

    Sponsors and Exhibitors
    http://www.experimentica.com

    Experimentica Ltd. is a Finland-based contract research organisation (CRO) dedicated to developing and offering preclinical ocular models and services to clients in the pharmaceutical, biotech and academic sectors. Founded in 2013 Experimentica Ltd. offers exclusively in-house expertise and an industry-leading portfolio of functional assays and in vivo imaging for preclinical ocular models. The mission of Experimentica Ltd. is to bridge a gap between the development of novel ocular models and their use in developing clinical applications.


    Nemera

    Sponsors and Exhibitors
    http://www.nemera.net

    Nemera is a world leader in the design, development and manufacturing of drug delivery devices for the pharmaceutical, biotechnology & generics industries. Nemera always puts patients first, providing services and products for several key delivery routes: Parenteral, Ophthalmic, Nasal, Buccal, Auricular, Inhalation, Dermal/Transdermal. Nemera leverages decades of experience in the parenteral device segment from full development to pure contract manufacturing, through customized solutions. Nemera developed: - Safe’n’Sound®, a fully passive safety device for prefilled syringes to avoid accidental needle-sticks. - Safelia®, a new generation of 2-steps auto-injector for fluid and viscous formulations.


    Ora

    Sponsors and Exhibitors
    http://www.oraclinical.com

    Ora is a global full-service ophthalmic clinical and preclinical CRO with offices in the United States, the United Kingdom, Australia and Japan. Ora supports all organizations, from start-ups to global pharmaceutical and device companies. In addition to turnkey CRO services, we provide strategic guidance and project execution in the regulatory, pre-clinical and CMC stages. Ora has also developed validated clinical models that are accepted as regulatory endpoints in allergy, dry eye and retina. We have a track record for accelerating development timelines and helping our clients garner 47 FDA approvals over the past 40 years. For more information, please visit www.oraclinical.com.

    Media Partners


    touchOPHTHALMOLOGY

    Official Online Media Partners
    http://www.touchophthalmology.com/

    touchOPHTHALMOLOGY.com is an independent information resource designed to support physicians, clinicians and related healthcare professionals in continuously developing their knowledge, effectiveness and productivity, with open access articles and multimedia content. touchOPHTHALMOLOGY.com is an independent information resource designed to support physicians, clinicians and related healthcare professionals in continuously developing their knowledge, effectiveness and productivity, with open access articles and multimedia content.

    Media Partners


    Gene Therapy Net

    Supporting Media Partners
    http://www.genetherapynet.com


    Media Partners


    CLocate

    Supporters
    http://www.clocate.com

    Clocate.com is a leading international directory for worldwide conferences and exhibitions. Clocate.com is equipped with a unique and comprehensive search that helps you find easily any event in any category or location. Each event includes detailed information, like, description, dates, location, map, prices, link to the official event's website and more...


    Drug Discovery Today

    Supporters
    http://www.drugdiscoverytoday.com/

    Drug Discovery Today is one of the most cited review journals in the field of drug discovery, with an impact factor of 6.422.
    Drug Discovery Today will benefit your research by helping to keep you up-to-date with all of the fast-moving and emerging topics in drug discovery. Each issue is packed full of the latest research news, peer-reviewed articles and comment and opinion from leading research scientists.


    Swiss Biotech Association

    Supporters
    http://www.swissbiotech.org/

    The Swiss Biotech Association (SBA) is the national industry association for biotechnology, including pharmaceuticals, diagnostics, agriculture, food, cosmetics, environmental biotechnology, and specialty chemicals. Members are companies active in modern biotechnology, such as R&D, Production, Marketing and Sales, Finance, Services and Consulting. SBA provides a networking platform for Life Science clusters, academic and federal institutions the like. Founded in March 1998, the Association grows steadily.


    Farmavita

    Supporters
    http://www.farmavita.net/

    Farmavita Net is professional community and network of pharmaceutical licensing and business development executives, innovators and researchers
    Farmavita.Net is the pharmaceutical licensing, technology transfer and regulatory affairs network. We are managing the marketplace of offers and demand for pharmaceutical Dossiers, know-how and technologies. Members of Farmavita.Net network usually find a number of attractive solutions for business development, alliances, joint ventures, co-development and co-marketing of pharmaceutical products. Farmavita.Net is not just a pure Internet portal. We manage a number of regional associates. We are connecting the dynamic network of few hundreds members / pharmaceutical companies interested in license-in and license-out opportunities.


    Journal for Clinical Studies – Your Resource for Multisite Studies & Emerging Markets

    Supporters
    http://www.JforCS.com

    Published bi-monthly.JCS is a unique journal, dedicated to providing information to the global pharmaceutical, biotechnology, medical devices and contract research organisations. JCS details practical and theoretical operational procedures, challenges, validatory and regulatory guidelines when conducting trials on a multisite basis and particularly within the emerging markets, naïve patient population, and remote access areas. JCS provides country by country objectives and uniquely brings you experiences in therapeutic areas of Liver diseases, kidney diseases, insect borne diseases, malnutrition and under nutrition. JCS is led by a strong editorial advisory board sourced out for their experiences; you will get the most practical insight for your global studies. JCS invites you to join us, write for us, feature your experiences with us, advertise your capabilities with us, and ask our advisory board for suggestions and guidelines. Let us make health care available to all.


    World Pharma News

    Supporters
    http://www.worldpharmanews.com/



    Drug Target Review

    Supporters
    http://www.drugtargetreview.com

    Drug Target Review’s quarterly magazine, website and annual events program provides high quality content with peer-written articles that are submitted exclusively by the world’s most respected scientists in their field. This attracts a committed base of readers, users and delegates made up of senior decision-makers from the life science and drug discovery industries at the top pharmaceutical companies, as well as academics and scientists from the top research institutes across the globe.


    Pharmavision

    Supporters
    http://www.pharmavision.co.uk

    PharmaVision offers a consultancy service providing independent pharmaceutical thematic research to the healthcare industry, the investment community and competitive intelligence specialists. We perform due diligence research and provide expert commentary in healthcare. Our reports combine scientific analysis in drug delivery, R&D technologies and pharmaceutical products including patient modelling, product/technology forecasts and market trends evaluation.


    Technology Networks

    Supporters
    http://go.technologynetworks.com/subscribe-to-newsletters

    Founded in 2000, Technology Networks is established as the leading news provider for life science and drug discovery professionals. In addition, we provide unique content including webcasts, videos, application notes and posters from recent conferences. Our portfolio now includes around 30 focussed scientific communities, all of which are accessible free of charge within TechnologyNetworks.com


    GBI

    Supporters
    http://www.gbihealth.com/

    GBI is an information, applications, and services company focused on the healthcare industry. Leveraging data from across the healthcare value chain, GBI creates web and mobile applications that enable individuals and organizations to make better decisions and communicate more effectively.


    ONdrugDelivery Magazine

    Supporters
    http://ondrugdelivery.com

    ONdrugDelivery Magazine is the highly regarded, world-leading series of sponsored themed drug delivery publications. Uniquely, each issue focuses tightly on one topic within the field of drug delivery. With a truly global readership already in excess of 40,000, and with contributions and loyal support from many of the most important companies in the drug delivery business - from among the largest to the smallest - ONdrugDelivery Magazine is a must for those in the industry who need to know what's going on in drug delivery.


    Pharmalicensing

    Supporters
    http://www.pharmalicensing.com

    Pharmalicensing (www.pharmalicensing.com) is the premier biopharmaceutical Open Innovation resource designed for professionals involved with partnering, licensing and business development worldwide. Actively supporting all forms of partnering and in- and out-licensing activities, Pharmalicensing utilizes the unique online Showcase Profiling & Discover services, as well as its renowned Partnering Search service leveraging its global network of industry experts, to enable companies to identify and engage with appropriate partners around the world. Pharmalicensing is actively utilized by many tens of thousands of industry professionals each month. Pharmalicensing is a division of Cognis Group, Inc.


    Gate2Biotech

    Supporters
    http://www.gate2biotech.com

    Gate2Biotech is a portal that unites biotechnological community in Central Europe. It covers all the news in the field of biotechnology. Thanks to the the portal the companies engaged in the field can easily search for research institutions and other partners to solve technical problems they are facing and here they can also present their services offer to potential partners from the Czech Republic and abroad. Gate2Biotech portal serves as a bridge connecting scientific and commercial sector. It incorporates offices and support organizations dedicated to promoting transfer of innovative technologies into a unified communication platform of Czech and international biotechnologies. As a mediator of information it draws attention to biotechnologies and support of their application and transfer into practice. It also functions as a tool for encouraging non-professionals (especially scientists and students) towards innovative business or applied research.


    Biocompare

    Supporters
    http://www.biocompare.com

    Biocompare.com is the leading resource for up-to-date product information, product reviews, and new technologies for life scientists. Biocompare combines an in-depth knowledge of life science products and new technologies with the power of the Internet to offer scientists the most dynamic, relevant, and innovative media-based marketplace for life science information.

    SAVE TO


    Outlook Calendar  OUTLOOK CALENDAR
    Google Calendar  GOOGLE CALENDAR
    ICal Calendar  ICAL CALENDAR
    Yahoo! Calendar  YAHOO! CALENDAR

    Copthorne Tara Hotel

    Scarsdale Place
    Kensington
    London W8 5SR
    United Kingdom

    Copthorne Tara Hotel

    The Copthorne Tara Hotel London Kensington is an elegant contemporary four-star hotel in prestigious Kensington, located just a two minutes walk from High Street Kensington underground station, making exploring easy. The hotel offers well-appointed and comfortable guest rooms combining Standard, Superior and Club accommodation. Club rooms offer iconic views over the city and include Club Lounge access for complimentary breakfast and refreshments. Guests can sample the authentic Singaporean, Malaysian and Chinese cuisine at Bugis Street, traditional pub fare at the Brasserie Restaurant & Bar or relax with a delicious drink at West8 Cocktail Lounge & Bar.

    The Copthorne Tara Hotel boasts 745 square meters of flexible meeting space, consisting of the Shannon Suite and the Liffey Suite, ideal for hosting conferences, weddings and social events. Facilities include access to the business centre 24 hours a day, fully equipped fitness room, gift shop, theatre desk and Bureau de Change. With ample onsite parking outside the London congestion charge zone and excellent transport links via Heathrow Airport, the hotel is the perfect location for business or leisure stays. The hotel is within close proximity to the shops of High Street Kensington, Knightsbridge and Westfield London, Olympia Conference Centre, Royal Albert Hall, Kensington Palace and Hyde Park.

     

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.

    Thank you for visiting our event

    If you would like to receive further information about our events, please fill out the information below.

    By ticking above you are consenting to receive information by email from SMi.
    Full details of our privacy policy can be found here https://www.smi-online.co.uk/privacy-legals/privacy-policy/.
    Should you wish to update your contact preferences at any time you can contact us at data@smi-online.co.uk.
    Should you wish to be removed from any future mailing lists please click on the following link http://www.smi-online.co.uk/opt-out